Indo-European Consortium for Next Generation Influenza Vaccine Innovation

Información del proyecto

INCENTIVE

Identificador del acuerdo de subvención: 874866

DOI

10.3030/874866

Proyecto cerrado

Fecha de la firma de la CE 13 Diciembre 2019

Fecha de inicio 1 Agosto 2020

Fecha de finalización 31 Enero 2026

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 19 965 992,50

Aportación de la UE

€ 9 974 293,75

Coordinado por

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (4)

INCENTIVE-QIV-1,2,3 (EU) and QIV-1 (India): Study results posted in the study registry

Safety and preliminary immunogenicity results posted on the study registry. Timelines if/when final posting of results is scheduled after end of funding period will be included.

INCENTIVE-QIV: Registration of the clinical trial in the trial registry

Study registered at a WHO or ICMJapproved registry

Development and annual update of INCENTIVE dissemination and exploitation plan delivered

Plan and annual update on dissemination activities and IP exploitation.

A blueprint for rolling out stratified influenza vaccination programs, in order to optimize / maximize efficiency and effectiveness taking into account acceptability, affordability and accessibility issues

Development of blueprint for the rollout of stratified influenza vaccination program.

Websites, patent fillings, videos etc. (1)

Project presentation prepared, website launched and communication plan developed

Setting up consortium website public and secured intranet Communication plan regulating the consortium communication

Publicaciones

Peer reviewed articles (14)

Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus

Autores: Camilla Tvedt Ekanger, Fan Zhou, Dana Bohan, Maria Lie Lotsberg, Maria Ramnefjell, Laurence Hoareau, Gro Vatne Røsland, Ning Lu, Marianne Aanerud, Fabian Gärtner, Pirjo Riitta Salminen, Mariann Bent
Publicado en: Frontiers in Cellular and Infection Microbiology, Edición 12, 2022, Página(s) 841447, ISSN 2235-2988
Editor: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.841447

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses

Autores: Nina Urke Ertesvåg, Rebecca Jane Cox, Sarah Larteley Lartey, Kristin G-I Mohn, Karl Albert Brokstad, Mai-Chi Trieu
Publicado en: npj Vaccines, Edición 7, 2022, Página(s) 490, ISSN 2059-0105
Editor: Springer Science and Business Media LLC
DOI: 10.1038/s41541-022-00490-0

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses

Autores: Naoko Uno, Thomas Ebensen, Carlos A. Guzman, Ted M. Ross
Publicado en: Journal of Virology, Edición 98, 2024, ISSN 0022-538X
Editor: American Society for Microbiology
DOI: 10.1128/jvi.00354-24

Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers

Autores: Mai-Chi Trieu, Amit Bansal, Marianne Sævik, Sonja Ljostveit, Åsne Jul-Larsen, Rebecca Jane Cox
Publicado en: npj Vaccines, Edición 10, 2025, Página(s) 1259, ISSN 2059-0105
Editor: Springer Science and Business Media LLC
DOI: 10.1038/s41541-025-01259-x

Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

Autores: Naoko Uno, Ted M. Ross
Publicado en: Human Vaccines & Immunotherapeutics, Edición 21, 2026, Página(s) 259961, ISSN 2164-5515
Editor: Landes Bioscience
DOI: 10.1080/21645515.2025.2599611

Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers

Autores: Lena Hansen, Fan Zhou, Håkon Amdam, Mai-Chi Trieu, Rebecca Jane Cox
Publicado en: Frontiers in Immunology, Edición 12, 2021, Página(s) 748264, ISSN 1664-3224
Editor: Frontiers Media SA
DOI: 10.3389/fimmu.2021.748264

Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine

Autores: Lukas Hoen, Sarah Lartey, Fan Zhou, Rishi D. Pathirana, Florian Krammer, Kristin G -I Mohn, Rebecca J. Cox, Karl A. Brokstad
Publicado en: Vaccines, Edición 12, 2025, Página(s) 864, ISSN 2076-393X
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines12080864

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection

Autores: Fan Zhou, Lena Hansen, Gabriel Pedersen, Gunnveig Grødeland, Rebecca Cox
Publicado en: Frontiers in Immunology, Edición 12, 2021, Página(s) 747774, ISSN 1664-3224
Editor: Frontiers Media SA
DOI: 10.3389/fimmu.2021.747774

Next Generation Influenza Vaccines: Looking into theCrystal Ball

Autores: Carlos Alberto Guzmán
Publicado en: Vaccines, 2020, ISSN 2076-393X
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030464

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection

Autores: Ane Marie Anderson, Elias Tjärnhage, Daniëla Maria Hinke, Ranveig Braathen, Gunnveig Grodeland, Bjarne Bogen
Publicado en: Molecular Therapy Nucleic Acids, Edición 37, 2026, Página(s) 102814, ISSN 2162-2531
Editor: Nature Publishing Group
DOI: 10.1016/j.omtn.2025.102814

Point-of-Care Influenza Testing Impacts Clinical Decision, Patient Flow, and Length of Stay in Hospitalized Adults

Autores: Elisabeth B Fjelltveit, Rebecca J Cox, Jørgen Østensjø, Bjørn Blomberg, Marit H Ebbesen, Nina Langeland, Kristin G I Mohn
Publicado en: The Journal of Infectious Diseases, Edición 226, 2022, Página(s) 97-108, ISSN 0022-1899
Editor: University of Chicago Press
DOI: 10.1093/infdis/jiaa690

Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review

Autores: Amit Bansal, Mai-Chi Trieu, Kristin G. I. Mohn, Rebecca Jane Cox
Publicado en: Frontiers in Immunology, Edición 12, 2021, Página(s) 744774, ISSN 1664-3224
Editor: Frontiers Media SA
DOI: 10.3389/fimmu.2021.744774

Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses

Autores: Naoko Uno, Ted M. Ross
Publicado en: Scientific Reports, Edición 14, 2024, ISSN 2045-2322
Editor: Nature Publishing Group
DOI: 10.1038/s41598-023-51024-0

Prospects and Challenges in the Development of Universal Influenza Vaccines

Autores: Anders Madsen, Rebecca Jane Cox
Publicado en: Vaccines, Edición 8, 2025, Página(s) 361, ISSN 2076-393X
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030361